125 related articles for article (PubMed ID: 38375169)
1. Content analysis of IQOS direct mail and email marketing in the US.
Henderson KC; Kute NG; Popova L; Ashley DL; Spears CA; Churchill V; Weaver SR; Pechacek TF; Huang J
Prev Med Rep; 2024 Feb; 38():102634. PubMed ID: 38375169
[TBL] [Abstract][Full Text] [Related]
2. IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers.
Berg CJ; Abroms LC; Levine H; Romm KF; Khayat A; Wysota CN; Duan Z; Bar-Zeev Y
Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639851
[TBL] [Abstract][Full Text] [Related]
3. Brief report on IQOS point-of-sale marketing, promotion and pricing in IQOS retail partner stores in Atlanta, Georgia, USA.
Henderson KC; Van Do V; Wang Y; Duan Z; Popova L; Spears CA; Weaver SR; Ashley DL; Barker DC; Huang J
Tob Control; 2023 Aug; 32(e2):e260-e264. PubMed ID: 35918133
[TBL] [Abstract][Full Text] [Related]
4. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
Lempert LK; Bialous S; Glantz S
Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
[TBL] [Abstract][Full Text] [Related]
5. Correlates of Perceptions, Use, and Intention to Use Heated Tobacco Products Among US Young Adults in 2020.
Duan Z; Wysota CN; Romm KF; Levine H; Bar-Zeev Y; Choi K; Berg CJ
Nicotine Tob Res; 2022 Nov; 24(12):1968-1977. PubMed ID: 35901840
[TBL] [Abstract][Full Text] [Related]
6. Characterizing Heated Tobacco Products Marketing on Instagram: Observational Study.
Chen J; Xue S; Xie Z; Li D
JMIR Form Res; 2023 Mar; 7():e43334. PubMed ID: 36920463
[TBL] [Abstract][Full Text] [Related]
7. Unboxed: US Young Adult Tobacco Users' Responses to a New Heated Tobacco Product.
Kim M; Watkins SL; Koester KA; Mock J; Kim HC; Olson S; Harvanko AM; Ling PM
Int J Environ Res Public Health; 2020 Nov; 17(21):. PubMed ID: 33153143
[TBL] [Abstract][Full Text] [Related]
8. Anticipating IQOS market expansion in the United States.
Abroms L; Levine H; Romm K; Wysota C; Broniatowski D; Bar-Zeev Y; Berg C
Tob Prev Cessat; 2022; 8():04. PubMed ID: 35174298
[TBL] [Abstract][Full Text] [Related]
9. Marketing IQOS in a dark market.
Mathers A; Schwartz R; O'Connor S; Fung M; Diemert L
Tob Control; 2019 Mar; 28(2):237-238. PubMed ID: 29724866
[TBL] [Abstract][Full Text] [Related]
10. IQOS marketing strategies in the USA before and after US FDA modified risk tobacco product authorisation.
Berg CJ; Romm KF; Bar-Zeev Y; Abroms LC; Klinkhammer K; Wysota CN; Khayat A; Broniatowski DA; Levine H
Tob Control; 2023 Jul; 32(4):418-427. PubMed ID: 34667105
[TBL] [Abstract][Full Text] [Related]
11. Heated tobacco products likely appeal to adolescents and young adults.
McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
[TBL] [Abstract][Full Text] [Related]
12. IQOS Marketing Strategies and Expenditures in the United States From Market Entrance in 2019 to Withdrawal in 2021.
Duan Z; Levine H; Romm KF; Bar-Zeev Y; Abroms LC; Griffith L; Wang Y; Khayat A; Cui Y; Berg CJ
Nicotine Tob Res; 2023 Sep; 25(11):1798-1803. PubMed ID: 37338204
[TBL] [Abstract][Full Text] [Related]
13. An Investigation of Influential Users in the Promotion and Marketing of Heated Tobacco Products on Instagram: A Social Network Analysis.
Gu J; Abroms LC; Broniatowski DA; Evans WD
Int J Environ Res Public Health; 2022 Feb; 19(3):. PubMed ID: 35162709
[TBL] [Abstract][Full Text] [Related]
14. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
[TBL] [Abstract][Full Text] [Related]
15. Industry marketing of tobacco products on social media: case study of Philip Morris International's IQOS.
Abroms LC; Wysota CN; Tosakoon S; Khayat A; Duan Z; Bar-Zeev Y; Berg CJ; Levine H
Tob Control; 2024 Jun; 33(4):518-524. PubMed ID: 36927516
[TBL] [Abstract][Full Text] [Related]
16. Assessment of IQOS Marketing Strategies at Points-of-Sale in Israel at a Time of Regulatory Transition.
Bar-Zeev Y; Berg CJ; Abroms LC; Rodnay M; Elbaz D; Khayat A; Levine H
Nicotine Tob Res; 2022 Jan; 24(1):100-108. PubMed ID: 34216461
[TBL] [Abstract][Full Text] [Related]
17. Point-of-sale marketing of heated tobacco products in Israel: cause for concern.
Halpern-Felsher B
Isr J Health Policy Res; 2019 May; 8(1):47. PubMed ID: 31133053
[TBL] [Abstract][Full Text] [Related]
18. IQOS print magazine advertising characteristics and reach before and after FDA authorisation as a modified risk tobacco product.
Ganz O; Strasser AA; Giovenco DP; Audrain-McGovern J; Cappella JN; Safi Z; Tan ASL; Talbot EM; Delnevo CD
Tob Control; 2023 Mar; ():. PubMed ID: 36958825
[TBL] [Abstract][Full Text] [Related]
19. Heated tobacco product regulation under US law and the FCTC.
Lempert LK; Glantz SA
Tob Control; 2018 Nov; 27(Suppl 1):s118-s125. PubMed ID: 30291201
[TBL] [Abstract][Full Text] [Related]
20. IQOS Use and Interest by Sociodemographic and Tobacco Behavior Characteristics among Adults in the US and Israel.
Levine H; Duan Z; Bar-Zeev Y; Abroms LC; Khayat A; Tosakoon S; Romm KF; Wang Y; Berg CJ
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
